- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
FDA grants fast-track designation to new gonorrhea vaccine
USA: The US Food and Drug Administration (FDA) has granted Fast Track designation to the investigational gonorrhoea vaccine developed by drugmaker GSK.
Fast Track designation accelerates the vaccine candidate’s path to US FDA submission to prevent Neisseria gonorrhoeae infection.
The vaccine candidate is currently in an ongoing Phase II trial and aims to demonstrate proof of concept by assessing the efficacy of the NgG vaccine in healthy adults, 18 to 50 years of age, considered at risk of gonorrhoea. Fast Track designation is intended to facilitate the development and expedite the review of potentially important new drugs and vaccines to treat or prevent serious conditions with unmet medical needs.
Gonorrhoea is the second most prevalent bacterial sexually transmitted infection (STI) worldwide, with an estimated 82 million new cases globally each year. In the US, rates of reported gonorrhoea have increased 118% from 2009 to 2021, resulting in 710,151 cases being reported to the US Centers for Disease Control and Prevention (CDC) in 2021.
Phil Dormitzer, Global Head of Vaccines R&D, GSK, said: “We welcome the FDA's decision to grant Fast Track designation for our new vaccine candidate against Neisseria gonorrhoeae infection. With a high and growing incidence, gonorrhoea is a major concern for sexual and reproductive health around the globe. This designation recognises the potential for a vaccine that could help protect millions of people worldwide against the serious health consequences of infection with a bacterium that is considered a ‘high priority’ pathogen by the World Health Organisation.”
Antimicrobial resistance (AMR) to gonorrhoea has increased over the past 80 years, rendering many antibiotics used to treat the disease ineffective.2 Vaccines can play a critical role in the fight against AMR by helping prevent bacterial, viral and other infections. At this time, there are no gonorrhoea vaccines approved anywhere in the world.4
About the Phase I/II trial
The trial conducted by GSK is a Phase I/II first time in human study (FTiH) evaluating the vaccine candidate’s safety and efficacy in individuals aged 18-50 years old, regardless of previous gonorrhoea history. Phase I of the study was a FTiH dose-escalation safety lead-in conducted in healthy adults and is now complete. Phase II of the study is ongoing and aims to demonstrate Proof of Concept by assessing the efficacy of the NgG vaccine in healthy adults considered at risk of gonorrhoea. The trial started in November 2022, and approximately 750 subjects will be enrolled from 8 countries (US, UK, France, Germany, Spain, Brazil, Philippines, South Africa).
About Gonorrhoea
Gonorrhoea is a sexually transmitted infection (STI) caused by a bacterium called Neisseria gonorrhoeae (Ng). It is recognised as an urgent unmet medical need due to its growing global incidence and reduced efficacy of available treatments as drug-resistant strains are increasing.2 Ng infection in women is often asymptomatic and under-diagnosed. When left untreated, Ng infection can lead to complications and long-term consequences such as pelvic inflammatory disease, infertility, ectopic pregnancy, and adverse pregnancy outcomes.4 Painful symptoms in men make gonorrhoea more likely to be diagnosed,5 but stigma surrounding the disease is still a barrier to seeking diagnosis and treatment. It has also been shown that Ng infections may also increase the risks of acquiring or transmitting HIV.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751